The relationship between triglyceride glucose body mass index, high density lipoprotein cholesterol to apolipoprotein A ratio, glycemic risk index and diabetic retinopathy

doi:10.11958/20241485

Abstract

Abstract:

Objective To investigate the relationship between triglyceride glucose body mass index (TyG-BMI), high density lipoprotein cholesterol to Apolipoprotein A ratio (HAR), glycemic risk index (GRI) and diabetic retinopathy (DR).Methods A total of 159 patients with type 2 diabetes mellitus (T2DM) complicated with DR (the DR group) were divided into the non-proliferative retinopathy group (NPDR group, 66 cases) and the proliferative retinopathy group (PDR group, 93 cases) according to DR international clinical grading criteria, and 159 T2DM patients without DR were selected as the control group. Clinical information and baseline laboratory test results were recorded, and TyG-BMI, HAR and GRI were calculated. Multivariate Logistic regression analysis was conducted to analyze the related factors of the incidence of DR, and receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of TyG-BMI, HAR and GRI for DR.Results The duration of T2DM, the proportion of hypertension, diabetic nephropathy and diabetic foot, levels of HbA1c, homeostasis model insulin resistance index (HOMA-IR), total cholesterol (TC), C-reactive protein (CRP), TyG-BMI, HAR and GRI were higher in the DR group than those in the control group (P < 0.05). TyG-BMI, HAR and GRI were higher in the PDR group than those in the NPDR group (P < 0.05). Multivariate Logistic regression analysis showed that the longer course of T2DM disease [OR (95%CI) : 2.781 (1.398-5.534)], high TyG-BMI [2.036 (1.169-3.546)], high HAR [1.890 (1.090-3.280)] and high GRI [1.836 (1.065-3.167)] were risk factors for DR (P < 0.05). ROC curve analysis results showed that, the area under the curve (AUC) of combined TyG-BMI, HAR and GRI diagnosis of DR was higher than that of single diagnosis [0.940 (0.908-0.964), 0.864 (0.821-0.900), 0.796 (0.747-0.839) and 0.836 (0.790-0.875), all P < 0.05].Conclusion The increased TyG-BMI, HAR and GRI in T2DM patients is associated with the onset and severity of DR, and which can be used to assess the risk of DR.

Key words: diabetic retinopathy, triglyceride glucose body mass index (TyG-BMI), high-density lipoprotein cholesterol to apolipoprotein A ratio (HAR), glycemic risk index (GRI)

CLC Number:

R587.29

Figures/Tables 6

References 25

[1]	YIN L, ZHANG D, REN Q, et al. Prevalence and risk factors of diabetic retinopathy in diabetic patients:a community based cross-sectional study[J]. Medicine (Baltimore), 2020, 99(9):e19236. doi:10.1097/MD.0000000000019236.
[2]	惠延年. 神经血管单元与糖尿病视网膜病变[J]. 国际眼科杂志, 2023, 23(3):353-355.
	HUI Y N. Neurovascular unit and diabetic retinopathy[J]. International Journal of Ophthalmology, 2023, 23(3):353-355. doi:10.3980/j.issn.1672-5123.2023.3.01.
[3]	WANG X, LIU J, CHENG Z, et al. Triglyceride glucose-body mass index and the risk of diabetes: a general population-based cohort study[J]. Lipids Health Dis, 2021, 20(1):99. doi:10.1186/s12944-021-01532-7.
[4]	XIAO S, ZHANG Q, YANG H Y, et al. The association between triglyceride glucose-body mass index and all-cause and cardiovascular mortality in diabetes patients:a retrospective study from NHANES database[J]. Sci Rep, 2024, 14(1):13884. doi:10.1038/s41598-024-63886-z.
[5]	RAO H, JALALI J A, JOHNSTON T P, et al. Emerging roles of dyslipidemia and hyperglycemia in diabetic retinopathy: molecular mechanisms and clinical perspectives[J]. Front Endocrinol (Lausanne), 2021,12:620045. doi:10.3389/fendo.2021.620045.
[6]	RHEE E J, BYRNE C D, SUNG K C. The HDL cholesterol/apolipoprotein A-I ratio:an indicator of cardiovascular disease[J]. Curr Opin Endocrinol Diabetes Obes, 2017, 24(2):148-153. doi:10.1097/MED.00000000000000315.
[7]	GHAMDI A H A. Clinical predictors of diabetic retinopathy progression; a systematic review[J]. Curr Diabetes Rev, 2020, 16(3):242-247. doi:10.2174/157339981566619021512043.
[8]	ZHONG T, HE B, LI X, et al. Glycaemia risk index uncovers distinct glycaemic variability patterns associated with remission status in type 1 diabetes[J]. Diabetologia, 2024, 67(1):42-51. doi:10.1007/s00125-023-06042-y.
[9]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4):292-344.
	Diabetes Society of Chinese Medical Association. Guidelines for the prevention and treatment of type 2 diabetes in China (2017 edition)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(4):292-344.
[10]	ER L K, WU S, CHOU H H, et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals[J]. PLoS One, 2016, 11(3):e0149731. doi:10.1371/journal.pone.0149731.
[11]	VALERIA C, VALERIA F, ANDREA, et al. A comparative study using insulin pump therapy and continuous glucose monitoring in newly diagnosed very young children with type 1 diabetes: it is possible to bend the curve of HbA1c[J]. Acta Diabetologica, 2023, 60(12):1719-1726. doi:10.1007/s00592-023-02155-3.
[12]	NEELAM K, AUNG K C Y, ANG K, et al. Association of triglyceride glucose index with prevalence and incidence of diabetic retinopathy in a singaporean population[J]. Clin Ophthalmol, 2023, 17:445-454. doi:10.2147/OPTH.S382336.
[13]	BAO Y K, YAN Y, WILSON B, et al. Association of retinopathy and insulin resistance: NHANES 2005-2008[J]. Curr Eye Res, 2020, 45(2):173-176. doi:10.1080/02713683.2019.1659977.
[14]	YAO L, WANG X, ZHONG Y, et al. The triglyceride-glucose index is associated with diabetic retinopathy in Chinese patients with type 2 diabetes:a hospital-based,nested,case-control study[J]. Diabetes Metab Syndr Obes, 2021, 14:1547-1555. doi:10.2147/DMSO.S294408.
[15]	RAMÍREZ-VÉLEZ R, CORREA-RODRÍGUEZ M, CALDERÓN-GONZÁLEZ J C, et al. The association between insulin resistance and cytokines in adolescents with excess of adiposity[J]. Curr Probl Cardiol, 2024,5:102925. doi:10.1016/j.cpcardiol.2024.102925.
[16]	SONG B, ZHAO X, YAO T, et al. Triglyceride glucose-body mass index and risk of incident type 2 diabetes mellitus in Japanese people with normal glycemic level:a population-based longitudinal cohort study[J]. Front Endocrinol (Lausanne), 2022,13:907973. doi:10.3389/fendo.2022.907973.
[17]	LI N, TAN H, XIE A, et al. Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes[J]. BMC Endocr Disord, 2022, 22(1):101. doi:10.1186/s12902-022-00993-w.
[18]	ZHANG X, QIU B, WANG Q, et al. Dysregulated serum lipid metabolism promotes the occurrence and development of diabetic retinopathy associated with upregulated circulating levels of VEGF-A,VEGF-D,and PLGF[J]. Front Med (Lausanne), 2021,8:779413. doi:10.3389/fmed.2021.779413.
[19]	JI Z, LIU G, ZHANG R, et al. High-density lipoprotein cholesterol to apolipoprotein A-1 ratio is an important indicator predicting in-hospital death in patients with acute coronary syndrome[J]. Cardiol J, 2024, 31(2):251-260. doi:10.5603/CJ.a2022.0058.
[20]	SHU Y, ZHOU Q, SHAO Y, et al. BMI and plasma lipid levels with risk of proliferative diabetic retinopathy:a univariable and multivariable Mendelian randomization study[J]. Front Nutr, 2023,10:1099807. doi:10.3389/fnut.2023.109980.
[21]	ZHANG X, NIE Y, GONG Z, et al. Plasma apolipoproteins predicting the occurrence and severity of diabetic retinopathy in patients with type 2 diabetes mellitus[J]. Front Endocrinol (Lausanne), 2022,13:915575. doi:10.3389/fendo.2022.91557.
[22]	LIU Y, LI J, MA J, et al. The threshold of the severity of diabetic retinopathy below which intensive glycemic control is beneficial in diabetic patients:estimation using data from large randomized clinical trials[J]. J Diabetes Res, 2020,2020:8765139. doi:10.1155/2020/5498528.
[23]	KARAKUS K E, SHAH V N, KLONOFF D, et al. Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes[J]. Diabetes Obes Metab, 2023, 25(11):3144-3151. doi:10.1111/dom.15208.
[24]	GUO C, DESHPANDE M, NIU Y, et al. HIF-1α accumulation in response to transient hypoglycemia may worsen diabetic eye disease[J]. Cell Rep, 2023, 42(1):111976. doi:10.1016/j.celrep.2022.111976.
[25]	赖丽平, 刘贺, 黄锡岚, 等. 2型糖尿病患者的糖尿病视网膜病变患病率及危险因素[J]. 广西医学, 2022, 44(1):370-375.
	LAI L P, LIU H, HUANG X L, et al. Prevalence and risk factors of diabetic retinopathy in patients with type 2 diabetes mellitus[J]. Guangxi Medicine, 2022, 44(1):370-375. doi:10.11675/j.issn.0253-4304.2022.04.03.

组别		n	年龄/岁		男性		BMI/（kg/m²）		T2DM病程/年		高血压		高脂血症		糖尿病肾病		糖尿病足
对照组		159	56.05±11.38		90（56.60）		23.06±1.87		4.74±1.89		92（57.86）		73（45.91）		19（11.95）		10（6.29）
DR组		159	56.29±12.12		96（60.37）		23.21±1.92		7.40±2.10		117（73.58）		80（50.31）		43（27.04）		26（16.35）
t或χ²			0.181		0.466		0.696		11.836^＊＊		8.724^＊＊		0.617		11.540^＊＊		8.019^＊＊
组别	HbA1c/%			HOMA-IR		TC/（mmol/L）		CRP/（mg/L）		WBC/（×10⁹/L）		NEU/（×10⁹/L）		Scr/（μmol/L）		Hcy/（μmol/L）
对照组	7.15±1.65			2.99±1.24		5.20±0.45		9.30±2.30		10.17±2.32		6.52±1.78		69.90±8.93		8.71±2.06
DR组	8.90±2.08			3.66±1.71		5.61±0.68		11.50±2.73		10.56±2.51		6.63±1.89		72.38±10.66		9.15±2.06
t	8.319^＊＊			3.973^＊＊		6.311^＊＊		7.627^＊＊		1.440		0.516		1.250		1.899

组别		n	年龄/岁		男性		BMI/（kg/m²）		T2DM病程/年		高血压		高脂血症		糖尿病肾病		糖尿病足
对照组		159	56.05±11.38		90（56.60）		23.06±1.87		4.74±1.89		92（57.86）		73（45.91）		19（11.95）		10（6.29）
DR组		159	56.29±12.12		96（60.37）		23.21±1.92		7.40±2.10		117（73.58）		80（50.31）		43（27.04）		26（16.35）
t或χ²			0.181		0.466		0.696		11.836^＊＊		8.724^＊＊		0.617		11.540^＊＊		8.019^＊＊
组别	HbA1c/%			HOMA-IR		TC/（mmol/L）		CRP/（mg/L）		WBC/（×10⁹/L）		NEU/（×10⁹/L）		Scr/（μmol/L）		Hcy/（μmol/L）
对照组	7.15±1.65			2.99±1.24		5.20±0.45		9.30±2.30		10.17±2.32		6.52±1.78		69.90±8.93		8.71±2.06
DR组	8.90±2.08			3.66±1.71		5.61±0.68		11.50±2.73		10.56±2.51		6.63±1.89		72.38±10.66		9.15±2.06
t	8.319^＊＊			3.973^＊＊		6.311^＊＊		7.627^＊＊		1.440		0.516		1.250		1.899

组别	n	TyG-BMI	HAR	GRI
对照组	159	153.44±28.43	0.75±0.19	26.33±4.05
DR组	159	164.62±40.79	0.91±0.22	33.85±6.21
t		2.835^＊＊	6.583^＊＊	12.795^＊＊

组别	n	TyG-BMI	HAR	GRI
对照组	159	153.44±28.43	0.75±0.19	26.33±4.05
DR组	159	164.62±40.79	0.91±0.22	33.85±6.21
t		2.835^＊＊	6.583^＊＊	12.795^＊＊

组别	n	TyG-BMI	HAR	GRI
NPDR组	66	156.59±11.30	0.78±0.19	31.38±3.67
PDR组	93	167.77±13.67	0.98±0.14	35.39±2.94
t		5.456^＊＊	7.752^＊＊	7.632^＊＊